Opportunities and Needs to Advance Prevention of Substance Use Disorders.  Blanco C, Volkow ND.  JAMA Pediatr. 2025;179(5):487–488. doi:10.1001/jamapediatrics.2025.0007 Anmeldung erforderlich https://jamanetwork.com/journals/…

Patient Satisfaction and Resource Utilization Following Introduction of Long-Acting Injectable Buprenorphine (LAIB) in Scottish Prisons.  Sayers C, Mogford D.  Subst Abuse Rehabil. 2025 Apr 15;16:83-93. doi: 10.2147/SAR.S510467. PMID: 40…

Distributing aluminium foil as harm reduction strategy among people who use drugs in prison.  Clua-García R, Imbernón-Casas M.  Rev Esp Sanid Penit. 2025 Jan-Apr;27(1):10-16. doi: 10.18176/resp.00100. PMID: 40260931; PMCID: PMC11995871…

Patient perspectives of jail based MOUD treatment: views of individuals who have returned to the community following incarceration.  Santelices C, Ferguson W, Rottapel R, Pivovarova E, Evans E, Stopka T, Friedmann P.  Health Justice. 202…

Factors contributing to the expansion of medication for opioid use disorder (MOUD) within the New Hampshire Department of Corrections (NHDOC).  Clayman N, Eamranond P, Hanks H, Mitcheff M, RappaMannion L, York D, Mattis P, Guinen H, Carp A, Ol…

Escalating Doses of Buprenorphine for the Treatment of Buprenorphine-Induced Opioid Withdrawal.  Laxton SJ.  Cureus. 2025 Mar 13;17(3):e80527. doi: 10.7759/cureus.80527. PMID: 40225488; PMCID: PMC11993309. https://pmc.ncbi.nlm.nih.gov/a…